Obnyx contains the active substance Enzalutamide, a targeted oral therapy used in the treatment of advanced prostate cancer. It belongs to a group of medicines known as androgen receptor inhibitors. Prostate cancer often grows in response to male hormones called androgens. Obnyx is designed to block the effect of these hormones, helping to slow or stop the growth of cancer cells. It is commonly prescribed to men whose cancer has spread or continued to grow despite previous treatments, including hormone therapy.

Mechanism of Action
Enzalutamide works by targeting androgen receptors on prostate cancer cells. Androgens, such as testosterone, fuel the growth of prostate cancer. Obnyx prevents these hormones from attaching to their receptors on the cancer cells. It also stops the hormone-receptor complex from entering the cell nucleus and activating cancer-promoting genes. By interrupting this pathway at multiple levels, Obnyx reduces cancer cell growth and spread, even when testosterone levels are already being medically lowered.

Uses
Obnyx is used in the treatment of:

• Metastatic castration-resistant prostate cancer, which is prostate cancer that has spread and continues to grow despite low testosterone levels

• Non-metastatic castration-resistant prostate cancer, where the cancer has not spread but no longer responds to traditional hormone therapy

• Metastatic hormone-sensitive prostate cancer, where Obnyx is often used in combination with other therapies

  Adverse Effects
  While many patients tolerate Obnyx well, some side effects can occur. Common side effects include tiredness, weakness, hot flashes, high blood pressure, and joint or muscle pain. Some patients may experience difficulty sleeping, mood changes, or swelling in the legs and arms.

  More serious but less common effects may include seizures, especially in individuals with a prior history of neurological conditions. Falls and fractures may also occur in older adults, so caution is advised. There may be an increased risk of heart problems in some individuals, and regular monitoring is recommended during treatment.

  Patients are encouraged to report any signs of confusion, unusual weakness, chest pain, or episodes of fainting to their healthcare provider immediately.